Skip to Content

Insulet Corp

PODD: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$488.00LgtxjlxTblmwnzvb

COVID-19 Has Hardly Slowed Insulet's Rise; Raising Our Fair Value Estimate

Business Strategy and Outlook

With little direct competition in patch pumps, Insulet has been able to convert more users to its innovative, tubeless insulin pump. We expect meaningful profitability gains over the next five years.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of PODD so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center